DK3052492T3 - Kondenserede 1,4-dihydrodioxin-derivater som hæmmere af varmechok-transskriptionsfaktor 1 - Google Patents

Kondenserede 1,4-dihydrodioxin-derivater som hæmmere af varmechok-transskriptionsfaktor 1 Download PDF

Info

Publication number
DK3052492T3
DK3052492T3 DK14781644.1T DK14781644T DK3052492T3 DK 3052492 T3 DK3052492 T3 DK 3052492T3 DK 14781644 T DK14781644 T DK 14781644T DK 3052492 T3 DK3052492 T3 DK 3052492T3
Authority
DK
Denmark
Prior art keywords
dihydrodioxin
inhibitors
condensed
derivatives
transcription factor
Prior art date
Application number
DK14781644.1T
Other languages
English (en)
Inventor
Keith Jones
Carl Rye
Nicola Chessum
Matthew Cheeseman
Adele Elisa Pasqua
Kurt Gordon Pike
Paul Frank Faulder
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Application granted granted Critical
Publication of DK3052492T3 publication Critical patent/DK3052492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14781644.1T 2013-10-04 2014-10-03 Kondenserede 1,4-dihydrodioxin-derivater som hæmmere af varmechok-transskriptionsfaktor 1 DK3052492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317609.4A GB201317609D0 (en) 2013-10-04 2013-10-04 Inhibitor compounds
PCT/GB2014/052992 WO2015049535A1 (en) 2013-10-04 2014-10-03 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1

Publications (1)

Publication Number Publication Date
DK3052492T3 true DK3052492T3 (da) 2019-05-06

Family

ID=49630211

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19164724.7T DK3521286T3 (da) 2013-10-04 2014-10-03 Kondenserede 1,4-dihydrodioxinderivater som hæmmere af varmechoktransskriptionsfaktor 1
DK14781644.1T DK3052492T3 (da) 2013-10-04 2014-10-03 Kondenserede 1,4-dihydrodioxin-derivater som hæmmere af varmechok-transskriptionsfaktor 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19164724.7T DK3521286T3 (da) 2013-10-04 2014-10-03 Kondenserede 1,4-dihydrodioxinderivater som hæmmere af varmechoktransskriptionsfaktor 1

Country Status (21)

Country Link
US (4) US9701664B2 (da)
EP (2) EP3521286B1 (da)
JP (2) JP6500017B2 (da)
KR (1) KR102332232B1 (da)
CN (1) CN105814040B (da)
AU (1) AU2014330940B2 (da)
BR (1) BR112016007329B1 (da)
CA (1) CA2925182C (da)
DK (2) DK3521286T3 (da)
ES (2) ES2730705T3 (da)
GB (1) GB201317609D0 (da)
HK (1) HK1224285A1 (da)
IL (1) IL244452B (da)
MX (1) MX369952B (da)
PL (2) PL3521286T3 (da)
PT (2) PT3521286T (da)
RU (1) RU2671979C2 (da)
SG (1) SG11201602547PA (da)
TR (1) TR201908265T4 (da)
WO (1) WO2015049535A1 (da)
ZA (1) ZA201601223B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) * 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
WO2018162312A1 (en) 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
WO2019043208A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
WO2023057819A1 (en) 2021-10-06 2023-04-13 Institute Of Cancer Research Methods of treating cancer using hsf1 pathway inhibitors
WO2023111005A1 (en) 2021-12-14 2023-06-22 Wmt Ag Carboxamide substituted heteroaromatic compounds for treating cancer
WO2023194458A1 (en) 2022-04-05 2023-10-12 Wmt Ag N-(3-(benzo[b]thiophene-2-carboxamido)-phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide derivatives and related compounds as lactate/atp production inhibitors for the treatment of cancer

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137805A (en) 1988-03-18 1992-08-11 The General Hospital Corporation Method of diagnosing stress condition by specific binding of human heat shock factor
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JP2845623B2 (ja) 1990-11-26 1999-01-13 アメリカ合衆国 細胞のストレス転写因子
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
US6281229B1 (en) 1997-06-27 2001-08-28 Kaneka Corporation Heat shock factor activity inhibitors
ATE282591T1 (de) 1997-12-23 2004-12-15 Warner Lambert Co Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
SK286123B6 (sk) 1998-05-15 2008-04-07 Astrazeneca Ab Benzamidové deriváty, spôsob ich prípravy, farmaceutická kompozícia a ich použitie na prípravu liečiva na liečenie chorôb sprostredkovaných cytokínmi
MXPA01000895A (es) 1998-08-04 2002-08-20 Astrazeneca Ab Derivados de amida utiles como inhibidores de la produccion de citocinas.
WO2000018738A1 (en) 1998-09-25 2000-04-06 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
SK287238B6 (sk) 1999-03-17 2010-04-07 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
WO2000056341A1 (en) 1999-03-22 2000-09-28 Charterhouse Therapeutics Ltd. Chemical compounds and their uses
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7405080B2 (en) 2000-03-23 2008-07-29 Voellmy Richard W Compositions and methods relating to prevention of chemotherapy-induced alopecia
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
AU2001282400B2 (en) 2001-09-03 2009-04-23 Richard Voellmy Compositions and methods relating to prevention of chemotherapy-induced alopecia
WO2004004703A1 (ja) 2002-07-04 2004-01-15 Mitsui Chemicals, Inc. メタフェニレンジアミン誘導体
AU2003251944B2 (en) 2002-07-15 2008-06-26 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
GB0218260D0 (en) 2002-08-06 2002-09-11 Charterhouse Therapeutics Ltd Improvements in pharmaceutically useful compounds
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
EP1545535A4 (en) 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
AU2003272327A1 (en) 2002-09-11 2004-04-30 University Of Medicine And Dentistry Of New Jersey Methods of bone healing
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
EP2327796A1 (en) 2003-06-10 2011-06-01 The Trustees Of Boston University Detection methods for disorders of the lung
RU2006104697A (ru) 2003-07-16 2006-06-27 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) Лекарственное средство для лечения пигментации кожи
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005042496A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives and methods for inhibiting heparanase activity
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
BRPI0518126A (pt) 2004-10-15 2008-10-28 Astrazeneca Ab composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20090062222A1 (en) 2005-09-29 2009-03-05 Trustees Of Boston University Methods for Sensitizing Cancer Cells to Inhibitors
CA2629814C (en) 2005-11-14 2013-12-31 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
EP1830289A1 (en) 2005-11-30 2007-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carninoma classification and prognosis
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
US8466180B2 (en) 2006-09-11 2013-06-18 Syngenta Crop Protection Llc Insecticidal compounds
EP2094719A4 (en) 2006-12-19 2010-01-06 Genego Inc NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US8518649B2 (en) 2007-04-04 2013-08-27 {hacek over (S)}árka O. Southern Systems and methods for analyzing persistent homeostatic perturbations
US20100184747A1 (en) 2007-06-12 2010-07-22 Boehringer Ingelheim International Gmbh Indoline derivatives and their use in treating disease-states such as cancer
CN101896461A (zh) 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
JP2011523710A (ja) 2008-06-03 2011-08-18 チャン，ビン ヒートショック応答調節因子のスクリーニング方法
NZ590385A (en) 2008-06-26 2012-11-30 Dana Farber Cancer Inst Inc Signatures and determinants associated with metastasis and methods of use thereof
UA38601U (en) * 2008-07-17 2009-01-12 Львовский Национальный Медицинский Университет Имени Данилы Галицкого 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
EP2660596B1 (en) 2008-10-02 2018-06-13 Gaia Medical Institute Health test for a broad spectrum of health problems
EP2367545A1 (en) 2008-10-17 2011-09-28 Université Libre de Bruxelles Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
SG173473A1 (en) 2009-02-11 2011-09-29 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
KR101630432B1 (ko) 2009-08-28 2016-06-15 한국생명공학연구원 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
US20130133108A1 (en) 2010-08-25 2013-05-23 Katherine Warpeha Extracts from pirin+ and pirin- plants and uses thereof
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
US20140302042A1 (en) 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
EA201490553A1 (ru) 2011-09-02 2014-08-29 Новартис Аг Органические композиции для лечения связанных с hsf1 заболеваний
WO2013052888A1 (en) 2011-10-06 2013-04-11 Whitehead Institute For Biomedical Research Hsf 1 as a marker in tumor prognosis and treatment
US20150241436A1 (en) 2012-05-03 2015-08-27 Whitehead Institute For Biomedical Research Hsf1 and hsf1 cancer signature set genes and uses relating thereto
WO2013172640A1 (ko) 2012-05-14 2013-11-21 이화여자대학교 산학협력단 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
GB201317609D0 (en) * 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound

Also Published As

Publication number Publication date
CN105814040A (zh) 2016-07-27
EP3052492B1 (en) 2019-03-27
AU2014330940A1 (en) 2016-03-03
US20170037036A1 (en) 2017-02-09
CN105814040B (zh) 2019-07-30
US20220220097A1 (en) 2022-07-14
US11787786B2 (en) 2023-10-17
JP6732071B2 (ja) 2020-07-29
PL3521286T3 (pl) 2022-03-21
TR201908265T4 (tr) 2019-06-21
GB201317609D0 (en) 2013-11-20
EP3052492A1 (en) 2016-08-10
CA2925182A1 (en) 2015-04-09
US9701664B2 (en) 2017-07-11
HK1224285A1 (zh) 2017-08-18
KR102332232B1 (ko) 2021-11-29
JP2016531891A (ja) 2016-10-13
RU2671979C2 (ru) 2018-11-08
KR20160065950A (ko) 2016-06-09
AU2014330940B2 (en) 2018-03-15
JP2019135234A (ja) 2019-08-15
ES2730705T3 (es) 2019-11-12
IL244452A0 (en) 2016-04-21
ES2902124T3 (es) 2022-03-25
EP3521286A1 (en) 2019-08-07
DK3521286T3 (da) 2021-12-06
PL3052492T3 (pl) 2019-09-30
BR112016007329B1 (pt) 2021-02-02
EP3521286B1 (en) 2021-09-29
US11124501B2 (en) 2021-09-21
US20190106413A1 (en) 2019-04-11
WO2015049535A1 (en) 2015-04-09
MX2016004114A (es) 2016-06-06
IL244452B (en) 2020-06-30
US10189821B2 (en) 2019-01-29
US20160289216A1 (en) 2016-10-06
CA2925182C (en) 2022-10-04
ZA201601223B (en) 2020-08-26
PT3521286T (pt) 2021-12-30
BR112016007329A2 (pt) 2017-08-01
SG11201602547PA (en) 2016-04-28
RU2016117056A3 (da) 2018-05-29
JP6500017B2 (ja) 2019-04-10
RU2016117056A (ru) 2017-11-10
MX369952B (es) 2019-11-27
PT3052492T (pt) 2019-06-27

Similar Documents

Publication Publication Date Title
DK3464272T3 (da) Nye heterocykliske derivater som SHP2-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3786162T3 (da) Bipyrazolderivater som jak-inhibitorer
DK3521286T3 (da) Kondenserede 1,4-dihydrodioxinderivater som hæmmere af varmechoktransskriptionsfaktor 1
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3019496T3 (da) Pyrimidinderivater som kinaseinhibitorer
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3356345T3 (da) Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3003038T3 (da) 2h-1,2,3-triazolderivater som inhibitorer af fibrose
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3145420T3 (da) Intraoperativ fremgangsmåde til tracking
DK3342771T3 (da) Heterocykliske amider som kinaseinhibitorer
DK2958900T3 (da) 2-aminopyrimidinderivater til behandling af virusinfektioner
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK2981535T3 (da) Urinstofderivater, der er anvendelige som kinaseinhibitorer
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3436435T3 (da) Substituerede indolderivater som inhibitorer af replikation af denguevirus
DK3083617T3 (da) Isochromene derivater som phosphoinositid 3-kinase-inhibitorer
DK3041842T3 (da) Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen